Ranking · Trials
Active clinical trials
Interventional studies registered on ClinicalTrials.gov whose overall status is RECRUITING, NOT_YET_RECRUITING, ENROLLING_BY_INVITATION or ACTIVE_NOT_RECRUITING and whose conditions map to this cancer or one of its descendants in the NCIt hierarchy.
Computedci-active-trials-v1unit: counthigher = betterAll metrics
| Rank | Δ | Cancer | Active clinical trials (count) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Neoplasm | 20,102 | 100 | Medium confidence | clinicaltrials | inputs
ranking row 2580955 |
| 2 | = | Carcinoma | 7,356 | 99.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580956 |
| 3 | = | Secondary Malignant Neoplasm | 4,270 | 99.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580957 |
| 4 | = | Malignant Digestive System Neoplasm | 4,259 | 99.8 | Medium confidence | clinicaltrials | inputs
ranking row 2580958 |
| 5 | = | Malignant Neoplasm of Unknown Primary | 4,158 | 99.8 | Medium confidence | clinicaltrials | inputs
ranking row 2580959 |
| 6 | = | Carcinoma of Unknown Primary | 4,151 | 99.7 | Medium confidence | clinicaltrials | inputs
ranking row 2580960 |
| 7 | = | Malignant Genitourinary System Neoplasm | 3,543 | 99.6 | Medium confidence | clinicaltrials | inputs
ranking row 2580961 |
| 8 | = | Malignant Reproductive System Neoplasm | 2,800 | 99.6 | Medium confidence | clinicaltrials | inputs
ranking row 2580962 |
| 9 | = | Malignant Thoracic Neoplasm | 2,769 | 99.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580963 |
| 10 | = | Adenocarcinoma | 2,751 | 99.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580964 |
| 11 | = | Malignant Lung Neoplasm | 2,644 | 99.4 | Medium confidence | clinicaltrials | inputs
ranking row 2580966 |
| 11 | = | Malignant Respiratory System Neoplasm | 2,644 | 99.4 | Medium confidence | clinicaltrials | inputs
ranking row 2580965 |
| 13 | = | Malignant Breast Neoplasm | 2,627 | 99.3 | Medium confidence | clinicaltrials | inputs
ranking row 2580967 |
| 14 | = | Lymphoma | 2,473 | 99.2 | Medium confidence | clinicaltrials | inputs
ranking row 2580968 |
| 15 | = | Lymphoid Neoplasm | 2,420 | 99.2 | Medium confidence | clinicaltrials | inputs
ranking row 2580969 |
| 16 | = | Non-Hodgkin Lymphoma | 2,168 | 99.1 | Medium confidence | clinicaltrials | inputs
ranking row 2580970 |
| 17 | = | Lung Carcinoma | 2,127 | 99 | Medium confidence | clinicaltrials | inputs
ranking row 2580971 |
| 18 | = | Digestive System Carcinoma | 2,122 | 99 | Medium confidence | clinicaltrials | inputs
ranking row 2580972 |
| 19 | = | B-Cell Malignant Neoplasm | 2,083 | 98.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580973 |
| 20 | = | Leukemia | 1,769 | 98.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580974 |
| 21 | = | B-Cell Non-Hodgkin Lymphoma | 1,757 | 98.8 | Medium confidence | clinicaltrials | inputs
ranking row 2580975 |
| 22 | = | Non-Small Cell Carcinoma | 1,749 | 98.7 | Medium confidence | clinicaltrials | inputs
ranking row 2580976 |
| 23 | = | Lung Non-Small Cell Carcinoma | 1,746 | 98.7 | Medium confidence | clinicaltrials | inputs
ranking row 2580977 |
| 24 | = | Malignant Intestinal Neoplasm | 1,665 | 98.6 | Medium confidence | clinicaltrials | inputs
ranking row 2580978 |
| 25 | = | Malignant Large Intestinal Neoplasm | 1,621 | 98.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580979 |
| 26 | = | Malignant Colorectal Neoplasm | 1,564 | 98.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580980 |
| 27 | = | Genitourinary System Carcinoma | 1,496 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2580981 |
| 28 | = | Malignant Female Reproductive System Neoplasm | 1,462 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2580982 |
| 29 | = | Malignant Male Reproductive System Neoplasm | 1,449 | 98.3 | Medium confidence | clinicaltrials | inputs
ranking row 2580983 |
| 30 | = | Malignant Head and Neck Neoplasm | 1,430 | 98.2 | Medium confidence | clinicaltrials | inputs
ranking row 2580984 |
| 31 | = | Malignant Prostate Neoplasm | 1,375 | 98.2 | Medium confidence | clinicaltrials | inputs
ranking row 2580985 |
| 32 | = | Digestive System Adenocarcinoma | 1,373 | 98.1 | Medium confidence | clinicaltrials | inputs
ranking row 2580986 |
| 33 | = | Hepatopancreatobiliary Carcinoma | 1,359 | 98.1 | Medium confidence | clinicaltrials | inputs
ranking row 2580987 |
| 34 | = | Acute Leukemia | 1,260 | 98 | Medium confidence | clinicaltrials | inputs
ranking row 2580988 |
| 35 | = | Malignant Hepatobiliary Neoplasm | 1,157 | 97.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580989 |
| 36 | = | Malignant Bone Marrow Neoplasm | 1,034 | 97.9 | Medium confidence | clinicaltrials | inputs
ranking row 2580990 |
| 37 | = | Head and Neck Carcinoma | 1,012 | 97.8 | Medium confidence | clinicaltrials | inputs
ranking row 2580991 |
| 38 | = | Squamous Cell Carcinoma | 974 | 97.8 | Medium confidence | clinicaltrials | inputs
ranking row 2580992 |
| 39 | = | Myeloproliferative Neoplasm | 964 | 97.7 | Medium confidence | clinicaltrials | inputs
ranking row 2580993 |
| 40 | = | Malignant Nervous System Neoplasm | 954 | 97.6 | Medium confidence | clinicaltrials | inputs
ranking row 2580994 |
| 41 | = | Malignant Liver Neoplasm | 906 | 97.6 | Medium confidence | clinicaltrials | inputs
ranking row 2580995 |
| 42 | = | Malignant Pancreatic Neoplasm | 904 | 97.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580996 |
| 43 | = | Malignant Urinary System Neoplasm | 887 | 97.5 | Medium confidence | clinicaltrials | inputs
ranking row 2580997 |
| 44 | = | Breast Carcinoma | 872 | 97.4 | Medium confidence | clinicaltrials | inputs
ranking row 2580998 |
| 45 | = | Myeloid Leukemia | 862 | 97.3 | Medium confidence | clinicaltrials | inputs
ranking row 2580999 |
| 46 | = | Lymphoid Leukemia | 827 | 97.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581000 |
| 47 | = | Malignant Central Nervous System Neoplasm | 823 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581001 |
| 47 | = | Malignant Uterine Neoplasm | 823 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581002 |
| 49 | = | Multiple Myeloma | 814 | 97.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581003 |
| 50 | = | Primary Malignant Liver Neoplasm | 805 | 97 | Medium confidence | clinicaltrials | inputs
ranking row 2581004 |
| 51 | = | Mature B-Cell Non-Hodgkin Lymphoma | 792 | 97 | Medium confidence | clinicaltrials | inputs
ranking row 2581005 |
| 52 | = | Acute Myeloid Leukemia | 789 | 96.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581006 |
| 53 | = | Liver Carcinoma | 781 | 96.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581007 |
| 54 | = | Pancreatobiliary Carcinoma | 698 | 96.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581008 |
| 55 | = | Hepatocellular Carcinoma | 693 | 96.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581009 |
| 56 | = | Breast Adenocarcinoma | 685 | 96.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581010 |
| 57 | = | Malignant Ovarian Neoplasm | 684 | 96.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581011 |
| 58 | = | Urinary System Carcinoma | 670 | 96.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581012 |
| 59 | = | Malignant Gastric Neoplasm | 652 | 96.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581013 |
| 60 | = | Sarcoma | 634 | 96.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581014 |
| 61 | = | Malignant Neck Neoplasm | 607 | 96.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581015 |
| 62 | = | Invasive Malignant Neoplasm | 604 | 96.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581016 |
| 62 | = | Melanoma | 604 | 96.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581017 |
| 64 | = | Invasive Carcinoma | 603 | 96.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581018 |
| 65 | = | Head and Neck Squamous Cell Carcinoma | 591 | 96.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581019 |
| 66 | = | Malignant Glioma | 589 | 96.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581020 |
| 67 | = | Malignant Endocrine Neoplasm | 577 | 96 | Medium confidence | clinicaltrials | inputs
ranking row 2581021 |
| 68 | = | Endocrine Carcinoma | 575 | 95.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581022 |
| 69 | = | Precursor Lymphoid Neoplasm | 568 | 95.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581023 |
| 70 | = | Acute Lymphoblastic Leukemia | 547 | 95.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581024 |
| 71 | = | Anaplastic Malignant Neoplasm | 546 | 95.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581025 |
| 72 | = | Breast Carcinoma by Gene Expression Profile | 536 | 95.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581026 |
| 73 | = | WHO Grade 4 Glioma | 535 | 95.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581027 |
| 74 | = | Malignant Esophageal Neoplasm | 518 | 95.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581028 |
| 75 | = | Neuroendocrine Carcinoma | 515 | 95.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581029 |
| 76 | = | Adult-Type Diffuse Glioma | 510 | 95.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581030 |
| 77 | = | Malignant Urinary Tract Neoplasm | 507 | 95.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581031 |
| 78 | = | Malignant Cervical Neoplasm | 505 | 95.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581032 |
| 79 | = | High Grade Astrocytic Tumor | 495 | 95.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581033 |
| 80 | = | Pancreatic Carcinoma | 489 | 95.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581034 |
| 81 | = | Glioblastoma | 486 | 95.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581035 |
| 82 | = | Neck Carcinoma | 464 | 95.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581036 |
| 83 | = | Esophageal and Gastroesophageal Junction Carcinoma | 460 | 95 | Medium confidence | clinicaltrials | inputs
ranking row 2581037 |
| 84 | = | Female Reproductive System Carcinoma | 457 | 95 | Medium confidence | clinicaltrials | inputs
ranking row 2581038 |
| 85 | = | Malignant Kidney Neoplasm | 453 | 94.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581039 |
| 86 | = | Male Reproductive System Carcinoma | 450 | 94.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581040 |
| 86 | = | Malignant Anorectal Neoplasm | 450 | 94.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581041 |
| 88 | = | Malignant Solid Neoplasm | 429 | 94.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581042 |
| 89 | = | Prostate Carcinoma | 428 | 94.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581043 |
| 90 | = | Triple-Negative Breast Carcinoma | 416 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581044 |
| 91 | = | Malignant Pharyngeal Neoplasm | 411 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581045 |
| 91 | = | Malignant Uterine Corpus Neoplasm | 411 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581046 |
| 93 | = | Chronic Leukemia | 410 | 94.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581047 |
| 94 | = | Intestinal Carcinoma | 409 | 94.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581048 |
| 95 | = | Kidney Carcinoma | 398 | 94.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581049 |
| 96 | = | Small Cell Neuroendocrine Carcinoma | 396 | 94.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581050 |
| 97 | = | Lung Neuroendocrine Carcinoma | 389 | 94.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581051 |
| 98 | = | Malignant Rectal Neoplasm | 386 | 94.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581052 |
| 99 | = | Lung Small Cell Carcinoma | 381 | 94.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581053 |
| 100 | = | Urinary System Adenocarcinoma | 378 | 94 | Medium confidence | clinicaltrials | inputs
ranking row 2581054 |
| 101 | = | Renal Cell Carcinoma | 375 | 94 | Medium confidence | clinicaltrials | inputs
ranking row 2581055 |
| 102 | = | Throat Carcinoma | 369 | 93.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581056 |
| 103 | = | Malignant Biliary Tract Neoplasm | 364 | 93.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581057 |
| 104 | = | Malignant Exocrine Pancreas Neoplasm | 360 | 93.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581058 |
| 105 | = | Malignant Endometrial Neoplasm | 359 | 93.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581059 |
| 106 | = | Exocrine Pancreas Carcinoma | 358 | 93.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581060 |
| 107 | = | Pharyngeal Carcinoma | 357 | 93.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581061 |
| 108 | = | Pancreatic Adenocarcinoma | 356 | 93.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581062 |
| 109 | = | Diffuse Large B-Cell Lymphoma | 355 | 93.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581063 |
| 110 | = | Malignant Bladder Neoplasm | 346 | 93.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581065 |
| 110 | = | Non-Hodgkin Lymphoma by Clinical Course | 346 | 93.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581064 |
| 112 | = | Colorectal Carcinoma | 344 | 93.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581066 |
| 113 | = | Malignant Soft Tissue Neoplasm | 341 | 93.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581067 |
| 114 | = | Soft Tissue Sarcoma | 338 | 93.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581068 |
| 115 | = | Myelodysplastic Syndrome | 336 | 93.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581069 |
| 116 | = | Urinary Tract Carcinoma | 326 | 93 | Medium confidence | clinicaltrials | inputs
ranking row 2581070 |
| 117 | = | Malignant Skin Neoplasm | 320 | 93 | Medium confidence | clinicaltrials | inputs
ranking row 2581071 |
| 118 | = | Esophageal Carcinoma | 307 | 92.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581072 |
| 119 | = | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 297 | 92.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581073 |
| 120 | = | Malignant Ovarian Epithelial Tumor | 270 | 92.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581074 |
| 120 | = | Ovarian Carcinoma | 270 | 92.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581075 |
| 122 | = | Chronic Lymphocytic Leukemia | 264 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581076 |
| 123 | = | Childhood Malignant Neoplasm | 263 | 92.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581077 |
| 124 | = | Malignant Nasopharyngeal Neoplasm | 261 | 92.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581078 |
| 125 | = | Transitional Cell Carcinoma | 253 | 92.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581079 |
| 126 | = | Lymphoma by Site | 250 | 92.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581080 |
| 127 | = | Nasopharyngeal Carcinoma | 246 | 92.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581081 |
| 128 | = | Biliary Tract Carcinoma | 236 | 92.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581082 |
| 128 | = | Urothelial Carcinoma | 236 | 92.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581083 |
| 130 | = | Gastroesophageal Junction Carcinoma | 231 | 92.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581084 |
| 131 | = | Gastroesophageal Junction Adenocarcinoma | 228 | 92.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581085 |
| 132 | = | Malignant Colon Neoplasm | 225 | 92.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581087 |
| 132 | = | T-Cell Non-Hodgkin Lymphoma | 225 | 92.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581086 |
| 134 | = | Castration-Resistant Prostate Carcinoma | 221 | 92 | Medium confidence | clinicaltrials | inputs
ranking row 2581089 |
| 134 | = | Malignant Bile Duct Neoplasm | 221 | 92 | Medium confidence | clinicaltrials | inputs
ranking row 2581088 |
| 136 | = | Follicular Lymphoma | 216 | 91.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581090 |
| 137 | = | Esophageal Squamous Cell Carcinoma | 212 | 91.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581091 |
| 137 | = | Indolent Non-Hodgkin Lymphoma | 212 | 91.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581092 |
| 139 | = | Cholangiocarcinoma | 208 | 91.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581093 |
| 139 | = | Intraductal Papillary Neoplasm of the Bile Duct | 208 | 91.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581095 |
| 139 | = | Pancreatic Ductal Adenocarcinoma | 208 | 91.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581094 |
| 142 | = | Malignant Brain Neoplasm | 193 | 91.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581097 |
| 142 | = | Malignant Intracranial Neoplasm | 193 | 91.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581096 |
| 144 | = | Gastric Carcinoma | 183 | 91.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581098 |
| 145 | = | Aggressive Non-Hodgkin Lymphoma | 182 | 91.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581099 |
| 146 | = | Mantle Cell Lymphoma | 180 | 91.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581100 |
| 147 | = | Hodgkin Lymphoma | 179 | 91.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581101 |
| 148 | = | Malignant Thyroid Gland Neoplasm | 176 | 91.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581102 |
| 149 | = | Indolent B-Cell Non-Hodgkin Lymphoma | 172 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2581103 |
| 149 | = | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 172 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2581104 |
| 151 | = | Cervical Carcinoma | 169 | 90.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581105 |
| 152 | = | Malignant Fallopian Tube Neoplasm | 168 | 90.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581106 |
| 153 | = | B Lymphoblastic Leukemia/Lymphoma | 164 | 90.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581107 |
| 154 | = | Malignant Head and Neck Mucosal Neoplasm | 163 | 90.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581109 |
| 154 | = | Malignant Peritoneal and Retroperitoneal Neoplasm | 163 | 90.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581108 |
| 156 | = | Head and Neck Mucosal Squamous Cell Carcinoma | 160 | 90.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581110 |
| 157 | = | Female Reproductive System Adenocarcinoma | 158 | 90.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581111 |
| 158 | = | B Acute Lymphoblastic Leukemia | 152 | 90.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581112 |
| 159 | = | Clear Cell Adenocarcinoma | 150 | 90.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581113 |
| 160 | = | Malignant Lip and Oral Cavity Neoplasm | 149 | 90.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581114 |
| 161 | = | Primitive Neuroectodermal Tumor | 146 | 90.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581115 |
| 162 | = | Malignant Oropharyngeal Neoplasm | 143 | 90.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581116 |
| 163 | = | Bladder Carcinoma | 141 | 90.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581118 |
| 163 | = | Malignant Musculoskeletal Neoplasm | 141 | 90.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581117 |
| 165 | = | HER2-Positive Breast Carcinoma | 140 | 90.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581119 |
| 166 | = | Invasive Prostate Carcinoma | 139 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2581120 |
| 167 | = | Gastric Adenocarcinoma | 137 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2581123 |
| 167 | = | Neuroblastic Tumor | 137 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2581121 |
| 167 | = | Neuroblastoma | 137 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2581122 |
| 170 | = | Infection-Related Malignant Neoplasm | 133 | 89.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581124 |
| 170 | = | Prostate Adenocarcinoma | 133 | 89.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581125 |
| 172 | = | Virus-Related Malignant Neoplasm | 132 | 89.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581126 |
| 173 | = | Small Lymphocytic Lymphoma | 129 | 89.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581127 |
| 174 | = | Skin Carcinoma | 127 | 89.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581128 |
| 175 | = | Malignant Peritoneal Neoplasm | 124 | 89.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581129 |
| 176 | = | Encapsulated Glioma | 116 | 89.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581130 |
| 177 | = | Aggressive B-Cell Non-Hodgkin Lymphoma | 115 | 89.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581132 |
| 177 | = | Myelodysplastic/Myeloproliferative Neoplasm | 115 | 89.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581131 |
| 179 | = | Clear Cell Renal Cell Carcinoma | 114 | 89.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581133 |
| 179 | = | Colorectal Adenocarcinoma | 114 | 89.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581134 |
| 181 | = | Malignant Oral Cavity Neoplasm | 111 | 89.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581135 |
| 181 | = | Marginal Zone Lymphoma | 111 | 89.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581136 |
| 183 | = | Endometrial Carcinoma | 109 | 89 | Medium confidence | clinicaltrials | inputs
ranking row 2581137 |
| 184 | = | Oropharyngeal Carcinoma | 107 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581138 |
| 185 | = | Malignant Muscle Neoplasm | 106 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581139 |
| 185 | = | Myosarcoma | 106 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581140 |
| 185 | = | Pharyngeal Squamous Cell Carcinoma | 106 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581141 |
| 188 | = | Extrapulmonary Neuroendocrine Carcinoma | 105 | 88.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581142 |
| 189 | = | Invasive Breast Carcinoma | 103 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581143 |
| 190 | = | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 102 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581144 |
| 191 | = | Malignant Infratentorial Neoplasm | 99 | 88.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581146 |
| 191 | = | Osteosarcoma | 99 | 88.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581145 |
| 193 | = | Lip and Oral Cavity Carcinoma | 96 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581149 |
| 193 | = | Malignant Mesothelioma | 96 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581147 |
| 193 | = | Malignant Mixed Neoplasm | 96 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581148 |
| 193 | = | Thyroid Gland Carcinoma | 96 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581150 |
| 197 | = | Invasive Bladder Carcinoma | 95 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581151 |
| 198 | = | Myeloproliferative Neoplasm, BCR-ABL1 Negative | 94 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581152 |
| 198 | = | Oral Cavity Carcinoma | 94 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581153 |
| 198 | = | Rectal Carcinoma | 94 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581154 |
| 201 | = | Lung Non-Squamous Non-Small Cell Carcinoma | 93 | 87.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581155 |
| 201 | = | Oropharyngeal Squamous Cell Carcinoma | 93 | 87.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581156 |
| 203 | = | Cervical Non-Squamous Cell Carcinoma | 92 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581158 |
| 203 | = | Primary Peritoneal Carcinoma | 92 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581157 |
| 205 | = | Cervical Adenocarcinoma | 91 | 87.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581159 |
| 206 | = | Skin Squamous Cell Carcinoma | 89 | 87.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581160 |
| 207 | = | Non-Cutaneous Melanoma | 87 | 87.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581161 |
| 208 | = | Chronic Myelomonocytic Leukemia | 86 | 87.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581162 |
| 208 | = | Intrahepatic Cholangiocarcinoma | 86 | 87.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581163 |
| 210 | = | Serous Adenocarcinoma | 85 | 87.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581164 |
| 211 | = | High Grade B-Cell Lymphoma | 84 | 87.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581166 |
| 211 | = | Lip and Oral Cavity Squamous Cell Carcinoma | 84 | 87.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581165 |
| 213 | = | Malignant Eye Neoplasm | 83 | 87.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581167 |
| 213 | = | Oral Cavity Squamous Cell Carcinoma | 83 | 87.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581168 |
| 213 | = | Ovarian Adenocarcinoma | 83 | 87.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581169 |
| 216 | = | Central Nervous System Lymphoma | 81 | 87 | Medium confidence | clinicaltrials | inputs
ranking row 2581170 |
| 217 | = | Malignant Thymus Neoplasm | 80 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581171 |
| 218 | = | Childhood Leukemia | 79 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581172 |
| 219 | = | Cutaneous Melanoma | 78 | 86.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581173 |
| 220 | = | Childhood Acute Leukemia | 77 | 86.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581174 |
| 220 | = | Fallopian Tube Carcinoma | 77 | 86.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581175 |
| 222 | = | Ewing Sarcoma | 76 | 86.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581176 |
| 222 | = | Glioblastoma, IDH-Wildtype | 76 | 86.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581177 |
| 224 | = | High-Grade Glioma, NOS | 75 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581180 |
| 224 | = | Malignant Brain Glioma | 75 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581179 |
| 224 | = | Secondary Carcinoma | 75 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581178 |
| 227 | = | Carcinomatosis | 74 | 86.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581182 |
| 227 | = | Rhabdomyosarcoma | 74 | 86.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581183 |
| 227 | = | Virus-Related Carcinoma | 74 | 86.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581181 |
| 230 | = | Lymphoplasmacytic Lymphoma | 73 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581184 |
| 231 | = | Carcinoma In Situ | 72 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581186 |
| 231 | = | Central Nervous System Embryonal Tumor | 72 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581185 |
| 231 | = | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 72 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581187 |
| 234 | = | Esophageal Adenocarcinoma | 70 | 85.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581189 |
| 234 | = | Human Papillomavirus-Related Malignant Neoplasm | 70 | 85.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581188 |
| 236 | = | Cutaneous Lymphoma | 69 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581190 |
| 236 | = | Malignant Ovarian Serous Tumor | 69 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581191 |
| 236 | = | Ovarian Serous Adenocarcinoma | 69 | 85.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581192 |
| 239 | = | Malignant Anal Neoplasm | 68 | 85.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581193 |
| 240 | = | Childhood Acute Lymphoblastic Leukemia | 67 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581194 |
| 240 | = | Human Papillomavirus-Related Carcinoma | 67 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581195 |
| 240 | = | Primary Cutaneous Lymphoma | 67 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581196 |
| 240 | = | Primary Cutaneous Non-Hodgkin Lymphoma | 67 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581197 |
| 244 | = | Malignant Laryngeal Neoplasm | 66 | 85.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581199 |
| 244 | = | Malignant Soft Tissue Neoplasm of Uncertain Differentiation | 66 | 85.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581198 |
| 244 | = | Primary Myelofibrosis | 66 | 85.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581200 |
| 247 | = | Acute Leukemia of Ambiguous Lineage | 65 | 85.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581201 |
| 248 | = | Adult Acute Myeloid Leukemia | 64 | 85.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581203 |
| 248 | = | Malignant Mediastinal Neoplasm | 64 | 85.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581202 |
| 250 | = | Malignant Salivary Gland Neoplasm | 63 | 84.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581204 |
| 250 | = | Mediastinal Lymphoma | 63 | 84.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581205 |
| 252 | = | Aggressive T-Cell Non-Hodgkin Lymphoma | 62 | 84.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581207 |
| 252 | = | Malignant Cerebellar Neoplasm | 62 | 84.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581208 |
| 252 | = | Ocular Melanoma | 62 | 84.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581206 |
| 255 | = | Adenocarcinoma In Situ | 61 | 84.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581210 |
| 255 | = | Diffuse Midline Glioma | 61 | 84.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581211 |
| 255 | = | Medulloblastoma | 61 | 84.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581209 |
| 258 | = | Bladder Urothelial Carcinoma | 60 | 84.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581212 |
| 258 | = | Breast Ductal Carcinoma | 60 | 84.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581213 |
| 260 | = | Malignant Uveal Neoplasm | 59 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581214 |
| 260 | = | Mediastinal Non-Hodgkin Lymphoma | 59 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581216 |
| 260 | = | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 59 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581217 |
| 260 | = | Uveal Melanoma | 59 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581215 |
| 260 | = | Waldenstrom Macroglobulinemia | 59 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581218 |
| 265 | = | Breast Carcinoma In Situ | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581222 |
| 265 | = | Lymphoblastic Lymphoma | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581219 |
| 265 | = | Platinum-Resistant Malignant Female Reproductive System Neoplasm | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581223 |
| 265 | = | Primary Mediastinal Large B-Cell Lymphoma | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581224 |
| 265 | = | Thymus Lymphoma | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581221 |
| 265 | = | T Lymphoblastic Leukemia/Lymphoma | 58 | 84 | Medium confidence | clinicaltrials | inputs
ranking row 2581220 |
| 271 | = | Basal Cell Carcinoma | 57 | 83.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581225 |
| 271 | = | Early Stage Breast Carcinoma | 57 | 83.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581227 |
| 271 | = | Intraductal Carcinoma | 57 | 83.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581226 |
| 271 | = | WHO Grade 3 Glioma | 57 | 83.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581228 |
| 275 | = | Platinum-Resistant Ovarian Carcinoma | 56 | 83.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581229 |
| 276 | = | Endometrioid Adenocarcinoma | 55 | 83.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581230 |
| 276 | = | Non-Muscle Invasive Bladder Carcinoma | 55 | 83.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581232 |
| 276 | = | Primary Central Nervous System Lymphoma | 55 | 83.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581231 |
| 279 | = | Malignant Vulvar Neoplasm | 54 | 83.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581233 |
| 280 | = | Malignant Hypopharyngeal Neoplasm | 53 | 83.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581235 |
| 280 | = | Non-Small Cell Adenocarcinoma | 53 | 83.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581234 |
| 282 | = | Lung Adenocarcinoma | 52 | 83 | Medium confidence | clinicaltrials | inputs
ranking row 2581237 |
| 282 | = | Mixed Phenotype Acute Leukemia | 52 | 83 | Medium confidence | clinicaltrials | inputs
ranking row 2581238 |
| 282 | = | Rectal Adenocarcinoma | 52 | 83 | Medium confidence | clinicaltrials | inputs
ranking row 2581239 |
| 282 | = | Salivary Gland Carcinoma | 52 | 83 | Medium confidence | clinicaltrials | inputs
ranking row 2581236 |
| 286 | = | Breast Ductal Carcinoma In Situ | 51 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581241 |
| 286 | = | Merkel Cell Carcinoma | 51 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581242 |
| 286 | = | Papillary Carcinoma | 51 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581240 |
| 289 | = | Grade 3 Follicular Lymphoma | 50 | 82.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581245 |
| 289 | = | Laryngeal Carcinoma | 50 | 82.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581246 |
| 289 | = | Liposarcoma | 50 | 82.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581243 |
| 289 | = | Malignant Small Intestinal Neoplasm | 50 | 82.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581244 |
| 293 | = | Malignant Brain Stem Neoplasm | 49 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581247 |
| 294 | = | Diffuse Intrinsic Pontine Glioma | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581253 |
| 294 | = | Erythroid Neoplasm | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581248 |
| 294 | = | Female Reproductive System Endometrioid Adenocarcinoma | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581249 |
| 294 | = | Papillary Adenocarcinoma | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581250 |
| 294 | = | Renal Pelvis and Ureter Carcinoma | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581251 |
| 294 | = | T Acute Lymphoblastic Leukemia | 48 | 82.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581252 |
| 300 | = | Colon Carcinoma | 47 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581256 |
| 300 | = | Head and Neck Adenocarcinoma | 47 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581255 |
| 300 | = | Large Cell Carcinoma | 47 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581254 |
| 303 | = | Burkitt Lymphoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581263 |
| 303 | = | Extranodal Lymphoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581259 |
| 303 | = | Extranodal Non-Hodgkin Lymphoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581260 |
| 303 | = | Hypopharyngeal Carcinoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581264 |
| 303 | = | Polycythemia Vera | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581261 |
| 303 | = | Secondary Acute Myeloid Leukemia | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581257 |
| 303 | = | Undifferentiated Carcinoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581258 |
| 303 | = | Uterine Corpus Sarcoma | 46 | 81.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581262 |
| 311 | = | Adult Acute Lymphoblastic Leukemia | 44 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581266 |
| 311 | = | Malignant Germ Cell Tumor | 44 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581265 |
| 313 | = | Malignant Histiocytic and Dendritic Cell Neoplasm | 43 | 81.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581267 |
| 313 | = | Malignant Penile Neoplasm | 43 | 81.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581270 |
| 313 | = | Malignant Testicular Neoplasm | 43 | 81.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581271 |
| 313 | = | Thyroid Gland Adenocarcinoma | 43 | 81.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581268 |
| 313 | = | Transformed Non-Hodgkin Lymphoma | 43 | 81.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581269 |
| 318 | = | Peritoneal Carcinomatosis | 42 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581272 |
| 318 | = | Small Intestinal Carcinoma | 42 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581273 |
| 320 | = | Classic Hodgkin Lymphoma | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581275 |
| 320 | = | Endometrial Adenocarcinoma | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581278 |
| 320 | = | Human Papillomavirus-Related Squamous Cell Carcinoma | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581276 |
| 320 | = | Laryngeal Squamous Cell Carcinoma | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581279 |
| 320 | = | Malignant Meningeal Neoplasm | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581277 |
| 320 | = | Malignant Retroperitoneal Neoplasm | 41 | 80.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581274 |
| 326 | = | Leiomyosarcoma | 38 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581281 |
| 326 | = | Malignant Bone Neoplasm | 38 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581280 |
| 328 | = | Anal Carcinoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581286 |
| 328 | = | Anaplastic Astrocytoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581283 |
| 328 | = | Differentiated Thyroid Gland Carcinoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581287 |
| 328 | = | Lung Squamous Cell Carcinoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581285 |
| 328 | = | Malignant Cardiovascular Neoplasm | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581282 |
| 328 | = | Mixed Carcinoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581284 |
| 328 | = | Renal Non-Clear Cell Carcinoma | 37 | 80.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581288 |
| 335 | = | Hormone Receptor-Positive Breast Carcinoma | 36 | 79.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581292 |
| 335 | = | Malignant Blood Vessel Neoplasm | 36 | 79.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581291 |
| 335 | = | Malignant Vascular Neoplasm | 36 | 79.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581289 |
| 335 | = | Non-Clear Cell Renal Cell Carcinoma | 36 | 79.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581293 |
| 335 | = | Virus-Related Lymphoma | 36 | 79.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581290 |
| 340 | = | Head and Neck Carcinoma, Other | 35 | 79.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581295 |
| 340 | = | Hypopharyngeal Squamous Cell Carcinoma | 35 | 79.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581294 |
| 342 | = | Muscle Invasive Bladder Carcinoma | 34 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581297 |
| 342 | = | Smoldering Multiple Myeloma | 34 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581296 |
| 344 | = | Indolent T-Cell Non-Hodgkin Lymphoma | 33 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581299 |
| 344 | = | Synovial Sarcoma | 33 | 79.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581298 |
| 346 | = | Malignant Gallbladder Neoplasm | 32 | 79.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581300 |
| 346 | = | Mycosis Fungoides and Sezary Syndrome | 32 | 79.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581301 |
| 348 | = | Adult Lymphoma | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581304 |
| 348 | = | Human Papillomavirus-Related Head and Neck Mucosal Squamous Cell Carcinoma | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581307 |
| 348 | = | Malignant Ovarian Endometrioid Tumor | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581306 |
| 348 | = | Malignant Sinonasal Neoplasm | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581305 |
| 348 | = | Malignant Vaginal Neoplasm | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581308 |
| 348 | = | Ovarian Endometrioid Adenocarcinoma | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581309 |
| 348 | = | Tobacco-Related Carcinoma | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581302 |
| 348 | = | Wilms Tumor | 31 | 79 | Medium confidence | clinicaltrials | inputs
ranking row 2581303 |
| 356 | = | Acute Myeloid Leukemia with Genetic Abnormalities | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581311 |
| 356 | = | Adenoid Cystic Carcinoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581310 |
| 356 | = | Gliosarcoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581312 |
| 356 | = | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581318 |
| 356 | = | High Grade Serous Adenocarcinoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581313 |
| 356 | = | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581319 |
| 356 | = | Human Papillomavirus-Related Pharyngeal Squamous Cell Carcinoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581317 |
| 356 | = | Malignant Extrahepatic Bile Duct Neoplasm | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581314 |
| 356 | = | Mycosis Fungoides | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581315 |
| 356 | = | Renal Pelvis and Ureter Urothelial Carcinoma | 30 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581316 |
| 366 | = | Extrahepatic Cholangiocarcinoma | 29 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581323 |
| 366 | = | Fallopian Tube Adenocarcinoma | 29 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581320 |
| 366 | = | HER2-Negative Breast Carcinoma | 29 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581321 |
| 366 | = | Ovarian High Grade Serous Adenocarcinoma | 29 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581324 |
| 366 | = | Thyroid Gland Papillary Carcinoma | 29 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581322 |
| 371 | = | Adenosquamous Carcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581327 |
| 371 | = | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581328 |
| 371 | = | Colon Adenocarcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581335 |
| 371 | = | Female Reproductive System Squamous Cell Carcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581329 |
| 371 | = | Malignant Adrenal Gland Neoplasm | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581330 |
| 371 | = | Malignant Appendix Neoplasm | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581326 |
| 371 | = | Meningeal Carcinomatosis | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581333 |
| 371 | = | Primary Peritoneal Adenocarcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581331 |
| 371 | = | Primary Peritoneal Serous Adenocarcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581334 |
| 371 | = | Sinonasal Carcinoma | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581332 |
| 371 | = | Therapy-Related Malignant Neoplasm | 28 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581325 |
| 382 | = | Female Reproductive System Clear Cell Adenocarcinoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581342 |
| 382 | = | Head and Neck Neuroendocrine Carcinoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581337 |
| 382 | = | Invasive Urothelial Carcinoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581338 |
| 382 | = | Mucinous Adenocarcinoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581339 |
| 382 | = | Mucosal Melanoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581340 |
| 382 | = | Rare Childhood Malignant Neoplasm | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581336 |
| 382 | = | Transformed B-Cell Non-Hodgkin Lymphoma | 27 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2581341 |
| 389 | = | Adrenal Cortical Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581349 |
| 389 | = | Anaplastic Large Cell Lymphoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581344 |
| 389 | = | Bone Sarcoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581345 |
| 389 | = | Breast Lobular Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581352 |
| 389 | = | Classic Follicular Lymphoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581356 |
| 389 | = | Grade 3b Follicular Lymphoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581357 |
| 389 | = | Head and Neck Undifferentiated Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581350 |
| 389 | = | Hepatoblastoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581343 |
| 389 | = | HHV8-Related Malignant Neoplasm | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581351 |
| 389 | = | Invasive Bladder Urothelial Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581353 |
| 389 | = | Malignant Adrenal Cortical Neoplasm | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581354 |
| 389 | = | Malignant Pleural Neoplasm | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581346 |
| 389 | = | Megakaryocytic Neoplasm | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581347 |
| 389 | = | Pediatric-Type Diffuse High-Grade Glioma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581358 |
| 389 | = | Retroperitoneal Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581348 |
| 389 | = | Vulvar Carcinoma | 26 | 76.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581355 |
| 405 | = | Childhood Carcinoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581360 |
| 405 | = | Hereditary Malignant Neoplasm | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581359 |
| 405 | = | Interdigitating Dendritic Cell Sarcoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581361 |
| 405 | = | Nasal Type Extranodal NK/T-Cell Lymphoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581363 |
| 405 | = | Penile Carcinoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581364 |
| 405 | = | Small Intestinal Adenocarcinoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581365 |
| 405 | = | Thyroid Gland Medullary Carcinoma | 25 | 75.6 | Medium confidence | clinicaltrials | inputs
ranking row 2581362 |
| 412 | = | Adult Non-Hodgkin Lymphoma | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581368 |
| 412 | = | Anal Squamous Cell Carcinoma | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581369 |
| 412 | = | Childhood Malignant Digestive System Neoplasm | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581366 |
| 412 | = | Essential Thrombocythemia | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581370 |
| 412 | = | Fallopian Tube Serous Adenocarcinoma | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581371 |
| 412 | = | Malignant Supratentorial Neoplasm | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581372 |
| 412 | = | Pleural Malignant Mesothelioma | 24 | 75.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581367 |
| 419 | = | Head and Neck Cutaneous Carcinoma | 23 | 74.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581374 |
| 419 | = | Head and Neck Cutaneous Squamous Cell Carcinoma | 23 | 74.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581377 |
| 419 | = | Myelodysplastic Syndrome with Excess Blasts | 23 | 74.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581375 |
| 419 | = | Plasma Cell Leukemia | 23 | 74.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581373 |
| 419 | = | Undifferentiated Sarcoma | 23 | 74.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581376 |
| 424 | = | Adult Glioblastoma | 22 | 74.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581380 |
| 424 | = | Carcinosarcoma | 22 | 74.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581378 |
| 424 | = | Small Cell Sarcoma | 22 | 74.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581379 |
| 424 | = | Thyroid Gland Anaplastic Carcinoma | 22 | 74.4 | Medium confidence | clinicaltrials | inputs
ranking row 2581381 |
| 428 | = | Childhood Malignant Nervous System Neoplasm | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581383 |
| 428 | = | Chondrosarcoma | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581384 |
| 428 | = | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581386 |
| 428 | = | Grade 1 Follicular Lymphoma | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581388 |
| 428 | = | Hairy Cell Leukemia | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581385 |
| 428 | = | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581389 |
| 428 | = | Malignant Splenic Neoplasm | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581382 |
| 428 | = | Malignant Urethral Neoplasm | 21 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581387 |
| 436 | = | B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581402 |
| 436 | = | Diffuse Midline Glioma, H3 K27-Altered | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581398 |
| 436 | = | EBV-Related Malignant Neoplasm | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581395 |
| 436 | = | Endometrial Endometrioid Adenocarcinoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581396 |
| 436 | = | Grade 2 Follicular Lymphoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581399 |
| 436 | = | Grade 3a Follicular Lymphoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581400 |
| 436 | = | Malignant Peripheral Nerve Sheath Tumor | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581390 |
| 436 | = | Malignant Peripheral Nervous System Neoplasm | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581391 |
| 436 | = | Myeloid Neoplasm Post Cytotoxic Therapy | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581392 |
| 436 | = | Sarcomatoid Carcinoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581393 |
| 436 | = | Thymus Carcinoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581394 |
| 436 | = | Type I Endometrial Adenocarcinoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581401 |
| 436 | = | Undifferentiated Pleomorphic Sarcoma | 20 | 73.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581397 |
| 449 | = | Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581403 |
| 449 | = | Ampulla of Vater Carcinoma | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581408 |
| 449 | = | Childhood Malignant Central Nervous System Neoplasm | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581404 |
| 449 | = | Dedifferentiated Liposarcoma | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581405 |
| 449 | = | Malignant Ampulla of Vater Neoplasm | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581407 |
| 449 | = | Malignant Ovarian Clear Cell Tumor | 19 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2581406 |
| 455 | = | Aggressive Adult Non-Hodgkin Lymphoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581415 |
| 455 | = | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581421 |
| 455 | = | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581416 |
| 455 | = | Brain Glioblastoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581411 |
| 455 | = | Fallopian Tube Endometrioid Adenocarcinoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581412 |
| 455 | = | Female Reproductive System Carcinosarcoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581413 |
| 455 | = | Gallbladder Carcinoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581417 |
| 455 | = | High Grade Endometrial Carcinoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581422 |
| 455 | = | Kaposi Sarcoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581418 |
| 455 | = | Malignant Duodenal Neoplasm | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581419 |
| 455 | = | Oligometastatic Malignant Neoplasm | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581409 |
| 455 | = | Ovarian Clear Cell Adenocarcinoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581420 |
| 455 | = | Therapy-Related Leukemia | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581410 |
| 455 | = | Virus-Related Sarcoma | 18 | 72.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581414 |
| 469 | = | Acute Myeloid Leukemia Post Cytotoxic Therapy | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581426 |
| 469 | = | Breast Inflammatory Carcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581431 |
| 469 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581434 |
| 469 | = | Diffuse Midline Glioma, H3 K27M-Mutant | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581437 |
| 469 | = | Follicular Helper T-Cell Lymphoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581435 |
| 469 | = | Germinomatous Germ Cell Tumor | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581423 |
| 469 | = | Human Papillomavirus-Related Cervical Carcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581432 |
| 469 | = | Malignant Ureter Neoplasm | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581433 |
| 469 | = | Penile Squamous Cell Carcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581427 |
| 469 | = | Prolymphocytic Leukemia | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581428 |
| 469 | = | Skin Basal Cell Carcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581429 |
| 469 | = | Solid Carcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581424 |
| 469 | = | Splenic Lymphoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581425 |
| 469 | = | Splenic Non-Hodgkin Lymphoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581430 |
| 469 | = | Type II Endometrial Adenocarcinoma | 17 | 71.7 | Medium confidence | clinicaltrials | inputs
ranking row 2581436 |
| 484 | = | Accelerated Phase Myeloproliferative Neoplasm | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581447 |
| 484 | = | Angiosarcoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581448 |
| 484 | = | Blastic Plasmacytoid Dendritic Cell Neoplasm | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581439 |
| 484 | = | Blast Phase Myeloproliferative Neoplasm | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581449 |
| 484 | = | Childhood Gastric Carcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581440 |
| 484 | = | Childhood Malignant Brain Neoplasm | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581450 |
| 484 | = | Desmoplastic Small Round Cell Tumor | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581441 |
| 484 | = | EBV-Related Lymphoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581442 |
| 484 | = | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581451 |
| 484 | = | Microsatellite Stable Colorectal Carcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581452 |
| 484 | = | Oligometastatic Carcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581443 |
| 484 | = | Plasmacytoid Dendritic Cell Neoplasm | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581438 |
| 484 | = | Platinum-Resistant Primary Peritoneal Carcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581444 |
| 484 | = | Primary Peritoneal High Grade Serous Adenocarcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581453 |
| 484 | = | Seminoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581445 |
| 484 | = | Soft Tissue Sarcoma of the Trunk and Extremities | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581446 |
| 484 | = | Sporadic Gastric Adenocarcinoma | 16 | 70.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581454 |
| 501 | = | Acral Melanoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581468 |
| 501 | = | Alveolar Soft Part Sarcoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581462 |
| 501 | = | Atypical Teratoid/Rhabdoid Tumor | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581457 |
| 501 | = | Cervical Squamous Cell Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581463 |
| 501 | = | Childhood Acute Myeloid Leukemia | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581469 |
| 501 | = | Chordoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581455 |
| 501 | = | Cigarette Smoking-Related Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581458 |
| 501 | = | Cutaneous Melanoma of the Extremity | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581464 |
| 501 | = | Digestive System Lymphoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581459 |
| 501 | = | EBV-Related Non-Hodgkin Lymphoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581465 |
| 501 | = | Endometrial Serous Adenocarcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581470 |
| 501 | = | Fallopian Tube High Grade Serous Adenocarcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581478 |
| 501 | = | Fibrosarcoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581460 |
| 501 | = | HER2-Positive Gastric Adenocarcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581479 |
| 501 | = | Immunodeficiency-Related Malignant Neoplasm | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581456 |
| 501 | = | Large Cell Neuroendocrine Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581466 |
| 501 | = | Lung Non-Small Cell Squamous Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581471 |
| 501 | = | Malignant Renal Pelvis Neoplasm | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581472 |
| 501 | = | Malignant Retinal Neoplasm | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581461 |
| 501 | = | Pediatric-Type Diffuse Low-Grade Glioma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581482 |
| 501 | = | Platinum-Resistant Fallopian Tube Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581480 |
| 501 | = | Platinum-Sensitive Malignant Female Reproductive System Neoplasm | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581473 |
| 501 | = | Platinum-Sensitive Ovarian Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581474 |
| 501 | = | Retinoblastoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581467 |
| 501 | = | Sinonasal Squamous Cell Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581475 |
| 501 | = | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581476 |
| 501 | = | Urethral Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581481 |
| 501 | = | Vaginal Carcinoma | 15 | 69.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581477 |
| 529 | = | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581490 |
| 529 | = | Acute Biphenotypic Leukemia | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581496 |
| 529 | = | Acute Promyelocytic Leukemia | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581499 |
| 529 | = | Appendix Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581484 |
| 529 | = | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581491 |
| 529 | = | Duodenal Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581497 |
| 529 | = | Early Gastric Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581500 |
| 529 | = | Female Reproductive System Undifferentiated Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581485 |
| 529 | = | Germ Cell Tumor, Brain | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581501 |
| 529 | = | HER2-Low Breast Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581492 |
| 529 | = | Juvenile Myelomonocytic Leukemia | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581483 |
| 529 | = | Myelodysplastic Syndrome/Acute Myeloid Leukemia | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581486 |
| 529 | = | Papillary Renal Cell Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581493 |
| 529 | = | Primary Brain Tumor | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581502 |
| 529 | = | Primary Peritoneal Endometrioid Adenocarcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581487 |
| 529 | = | Renal Pelvis Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581494 |
| 529 | = | Sarcomatoid Renal Cell Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581488 |
| 529 | = | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581498 |
| 529 | = | Ureter Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581495 |
| 529 | = | Vulvar Squamous Cell Carcinoma | 14 | 68.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581489 |
| 549 | = | Childhood Central Nervous System Embryonal Tumor | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581503 |
| 549 | = | Childhood Lymphoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581504 |
| 549 | = | Childhood Medulloblastoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581505 |
| 549 | = | Digestive System Non-Hodgkin Lymphoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581506 |
| 549 | = | Duodenal Adenocarcinoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581509 |
| 549 | = | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581507 |
| 549 | = | Extrapulmonary Small Cell Neuroendocrine Carcinoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581508 |
| 549 | = | High-Grade Serous Ovarian Cancer | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581511 |
| 549 | = | Hilar Cholangiocarcinoma | 13 | 66.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581510 |
| 558 | = | Adult B Acute Lymphoblastic Leukemia | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581518 |
| 558 | = | AIDS-Related Malignant Neoplasm | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581512 |
| 558 | = | Astrocytoma, IDH-Mutant, Grade 4 | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581513 |
| 558 | = | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581519 |
| 558 | = | Childhood Sarcoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581514 |
| 558 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581524 |
| 558 | = | Fallopian Tube Clear Cell Adenocarcinoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581521 |
| 558 | = | Ganglioneuroblastoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581515 |
| 558 | = | Leukemic Phase of Non-Hodgkin Lymphoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581516 |
| 558 | = | Malignant Cerebral Neoplasm | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581525 |
| 558 | = | Myxoid Liposarcoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581517 |
| 558 | = | Ovarian Carcinosarcoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581520 |
| 558 | = | Plasmablastic Lymphoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581522 |
| 558 | = | Ureter Urothelial Carcinoma | 12 | 66.3 | Medium confidence | clinicaltrials | inputs
ranking row 2581523 |
| 572 | = | Acute Myeloid Leukemia, Myelodysplasia-Related | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581530 |
| 572 | = | Acute Myeloid Leukemia, Not Otherwise Specified | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581531 |
| 572 | = | Acute Undifferentiated Leukemia | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581532 |
| 572 | = | Anaplastic Oligodendroglioma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581526 |
| 572 | = | Clear Cell Sarcoma of Soft Tissue | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581527 |
| 572 | = | Colorectal Carcinoma with Genetic Abnormalities | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581542 |
| 572 | = | Diffuse Large B-Cell Lymphoma Unclassifiable | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581533 |
| 572 | = | Early Stage Bladder Urothelial Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581543 |
| 572 | = | Female Reproductive System Adenosquamous Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581534 |
| 572 | = | Fibrolamellar Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581535 |
| 572 | = | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581547 |
| 572 | = | High Grade Follicular Cell-Derived Non-Anaplastic Thyroid Gland Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581536 |
| 572 | = | High Risk Neuroblastoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581537 |
| 572 | = | Malignant Tongue Neoplasm | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581538 |
| 572 | = | Nasopharyngeal Squamous Cell Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581544 |
| 572 | = | Poorly Differentiated Thyroid Gland Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581545 |
| 572 | = | Renal Pelvis Urothelial Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581546 |
| 572 | = | Retroperitoneal Sarcoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581528 |
| 572 | = | Sezary Syndrome | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581539 |
| 572 | = | Splenic Marginal Zone Lymphoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581540 |
| 572 | = | T Lymphoblastic Lymphoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581529 |
| 572 | = | Urethral Urothelial Carcinoma | 11 | 65.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581541 |
| 594 | = | Adult T-Cell Leukemia/Lymphoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581551 |
| 594 | = | ALK-Positive Lung Non-Small Cell Carcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581565 |
| 594 | = | AML with Recurrent Genetic Abnormalities | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581569 |
| 594 | = | Breast Lobular Carcinoma In Situ | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581549 |
| 594 | = | Cervical Adenosquamous Carcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581566 |
| 594 | = | Digestive System Neuroendocrine Carcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581550 |
| 594 | = | Epithelioid Sarcoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581552 |
| 594 | = | Extramammary Paget Disease | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581558 |
| 594 | = | Grade 3 Meningioma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581553 |
| 594 | = | Head and Neck Carcinoma of Unknown Primary | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581554 |
| 594 | = | HTLV-1-Related Malignant Neoplasm | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581555 |
| 594 | = | Lung Large Cell Neuroendocrine Carcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581559 |
| 594 | = | Lung Non-Small Cell Carcinoma with Genetic Abnormalities | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581560 |
| 594 | = | Malignant Abdominal Neoplasm | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581548 |
| 594 | = | Malignant Ovarian Mucinous Tumor | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581556 |
| 594 | = | MGMT-Unmethylated Glioblastoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581561 |
| 594 | = | Muscle Invasive Bladder Urothelial Carcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581567 |
| 594 | = | Nodal Marginal Zone Lymphoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581568 |
| 594 | = | Ovarian Mucinous Adenocarcinoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581562 |
| 594 | = | Paget Disease | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581557 |
| 594 | = | Pseudomyxoma Peritonei | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581563 |
| 594 | = | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 10 | 64.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581564 |
| 616 | = | Acute Monoblastic and Monocytic Leukemia | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581590 |
| 616 | = | Acute Monocytic Leukemia | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581593 |
| 616 | = | Adult Hodgkin Lymphoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581575 |
| 616 | = | B Lymphoblastic Lymphoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581576 |
| 616 | = | Childhood Non-Hodgkin Lymphoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581577 |
| 616 | = | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581597 |
| 616 | = | Endometrial Clear Cell Adenocarcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581591 |
| 616 | = | Fallopian Tube Transitional Cell Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581584 |
| 616 | = | Female Reproductive System Transitional Cell Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581578 |
| 616 | = | Human Papillomavirus-Related Anal Squamous Cell Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581585 |
| 616 | = | Intestinal Lymphoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581579 |
| 616 | = | Malignant Anal Canal Neoplasm | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581594 |
| 616 | = | Malignant Major Salivary Gland Neoplasm | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581580 |
| 616 | = | Malignant Mixed Mesodermal (Mullerian) Tumor | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581572 |
| 616 | = | Malignant Paranasal Sinus Neoplasm | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581581 |
| 616 | = | Malignant Pelvic Neoplasm | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581570 |
| 616 | = | Malignant Pineal Region Neoplasm | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581595 |
| 616 | = | Non-Muscle Invasive Bladder Urothelial Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581592 |
| 616 | = | Oligometastatic Prostate Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581586 |
| 616 | = | Ovarian Seromucinous Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581582 |
| 616 | = | Ovarian Transitional Cell Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581587 |
| 616 | = | Ovarian Undifferentiated Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581588 |
| 616 | = | Paranasal Sinus Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581589 |
| 616 | = | Periampullary Adenocarcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581596 |
| 616 | = | Peripheral Primitive Neuroectodermal Tumor | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581573 |
| 616 | = | Secondary Central Nervous System Lymphoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581583 |
| 616 | = | Thyroid Gland Follicular Carcinoma | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581571 |
| 616 | = | Yolk Sac Tumor | 9 | 62.8 | Medium confidence | clinicaltrials | inputs
ranking row 2581574 |
| 644 | = | Acinar Cell Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581601 |
| 644 | = | AIDS-Related Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581602 |
| 644 | = | Anal Canal Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581625 |
| 644 | = | Appendix Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581610 |
| 644 | = | Atypical Chronic Myeloid Leukemia | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581603 |
| 644 | = | Biliary Tract Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581611 |
| 644 | = | Childhood Soft Tissue Sarcoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581604 |
| 644 | = | Chromophobe Renal Cell Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581628 |
| 644 | = | Diffuse Hemispheric Glioma, H3 G34-Mutant | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581612 |
| 644 | = | Digestive System Adenosquamous Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581605 |
| 644 | = | Endometrial Low Grade Endometrioid Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581613 |
| 644 | = | Enteropathy-Associated T-Cell Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581629 |
| 644 | = | Gray-Zone Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581614 |
| 644 | = | Hereditary Breast Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581598 |
| 644 | = | Intestinal Non-Hodgkin Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581615 |
| 644 | = | Intestinal T-Cell Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581626 |
| 644 | = | Invasive Breast Lobular Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581616 |
| 644 | = | Low Grade Endometrioid Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581606 |
| 644 | = | Low Grade Serous Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581617 |
| 644 | = | Malignant Liver Non-Epithelial Neoplasm | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581618 |
| 644 | = | Malignant Skin Adnexal Neoplasm | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581599 |
| 644 | = | Myxofibrosarcoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581619 |
| 644 | = | Ovarian Low Grade Serous Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581627 |
| 644 | = | Pancreatic Adenosquamous Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581620 |
| 644 | = | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581621 |
| 644 | = | Primary Peritoneal Clear Cell Adenocarcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581622 |
| 644 | = | Prostate Neuroendocrine Carcinoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581607 |
| 644 | = | Secondary Myelodysplastic Syndrome | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581600 |
| 644 | = | Soft Tissue Fibrosarcoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581608 |
| 644 | = | T-Cell Large Granular Lymphocyte Leukemia | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581609 |
| 644 | = | T-Cell Prolymphocytic Leukemia | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581623 |
| 644 | = | Uterine Carcinosarcoma | 8 | 61.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581624 |
| 676 | = | Astrocytoma, IDH-Mutant, Grade 3 | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581634 |
| 676 | = | Bladder Non-Urothelial Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581655 |
| 676 | = | Castration-Sensitive Prostate Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581649 |
| 676 | = | Childhood B Acute Lymphoblastic Leukemia | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581635 |
| 676 | = | Childhood B Lymphoblastic Leukemia/Lymphoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581630 |
| 676 | = | Childhood Colorectal Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581636 |
| 676 | = | Childhood Malignant Intestinal Neoplasm | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581637 |
| 676 | = | Distal Cholangiocarcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581656 |
| 676 | = | Double-Expressor Lymphoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581650 |
| 676 | = | Early Stage Triple-Negative Breast Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581644 |
| 676 | = | Estrogen Receptor-Positive Breast Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581651 |
| 676 | = | Fallopian Tube Undifferentiated Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581645 |
| 676 | = | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581652 |
| 676 | = | FIGO Grade 1 Endometrioid Adenocarcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581646 |
| 676 | = | Liver Lymphoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581638 |
| 676 | = | Malignant Nasal Cavity Neoplasm | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581639 |
| 676 | = | Malignant Testicular Germ Cell Tumor | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581631 |
| 676 | = | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581632 |
| 676 | = | Myeloid Leukemia, Philadelphia-Positive | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581640 |
| 676 | = | Olfactory Neuroblastoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581641 |
| 676 | = | Pineoblastoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581633 |
| 676 | = | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581647 |
| 676 | = | Primary Cutaneous Diffuse Large B-Cell Lymphoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581653 |
| 676 | = | Primary Effusion Lymphoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581642 |
| 676 | = | Skin Adnexal Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581643 |
| 676 | = | Squamous Cell Carcinoma of Unknown Primary | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581648 |
| 676 | = | Urinary Tract Non-Urothelial Carcinoma | 7 | 59.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581654 |
| 703 | = | Acral Lentiginous Melanoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581693 |
| 703 | = | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581703 |
| 703 | = | Amyloidosis | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581706 |
| 703 | = | Anaplastic Large Cell Lymphoma, ALK-Positive | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581667 |
| 703 | = | Central Nervous System Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581659 |
| 703 | = | Childhood Malignant Solid Neoplasm | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581660 |
| 703 | = | Childhood Rhabdomyosarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581677 |
| 703 | = | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581678 |
| 703 | = | Chronic Myelomonocytic Leukemia-2 | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581679 |
| 703 | = | Collecting Duct Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581694 |
| 703 | = | Core Binding Factor Acute Myeloid Leukemia | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581702 |
| 703 | = | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581680 |
| 703 | = | Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581695 |
| 703 | = | Embryonal Tumor with Multilayered Rosettes | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581661 |
| 703 | = | Endometrial Mixed Cell Adenocarcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581696 |
| 703 | = | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581668 |
| 703 | = | Fallopian Tube Mucinous Adenocarcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581681 |
| 703 | = | Hepatosplenic T-Cell Lymphoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581682 |
| 703 | = | High Grade Sarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581662 |
| 703 | = | Hormone Receptor-Negative Breast Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581683 |
| 703 | = | Human Papillomavirus-Related Penile Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581684 |
| 703 | = | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581685 |
| 703 | = | Intravascular Large B-Cell Lymphoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581697 |
| 703 | = | Invasive Breast Carcinoma of No Special Type | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581686 |
| 703 | = | Kidney Medullary Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581698 |
| 703 | = | Kidney Wilms Tumor | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581663 |
| 703 | = | Liver Non-Hodgkin Lymphoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581687 |
| 703 | = | Low Grade Sarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581664 |
| 703 | = | Malignant Giant Cell Neoplasm | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581657 |
| 703 | = | MGMT-Methylated Glioblastoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581688 |
| 703 | = | Myelodysplastic Syndrome Post Cytotoxic Therapy | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581669 |
| 703 | = | Nasal Cavity Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581689 |
| 703 | = | Non-Keratinizing Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581670 |
| 703 | = | Non-Seminomatous Germ Cell Tumor | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581704 |
| 703 | = | Obesity-Related Malignant Neoplasm | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581658 |
| 703 | = | Oropharynx Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581705 |
| 703 | = | Pancreatic Acinar Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581690 |
| 703 | = | Pancreatic Neuroendocrine Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581671 |
| 703 | = | Paranasal Sinus Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581699 |
| 703 | = | Peritoneal Malignant Mesothelioma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581665 |
| 703 | = | Pharyngeal Carcinoma by AJCC v8 Stage | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581700 |
| 703 | = | Plasmacytoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581666 |
| 703 | = | Pleomorphic Liposarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581672 |
| 703 | = | Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581691 |
| 703 | = | Primary Peritoneal Carcinosarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581673 |
| 703 | = | Prostate Small Cell Neuroendocrine Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581692 |
| 703 | = | Tongue Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581701 |
| 703 | = | Uterine Corpus Carcinosarcoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581674 |
| 703 | = | Vaginal Adenocarcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581675 |
| 703 | = | Vaginal Squamous Cell Carcinoma | 6 | 57.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581676 |
| 753 | = | Acute Myeloid Leukemia with KMT2A Rearrangement | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581741 |
| 753 | = | Adult Lymphoblastic Lymphoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581717 |
| 753 | = | ALK-Positive Large B-Cell Lymphoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581735 |
| 753 | = | Alveolar Rhabdomyosarcoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581726 |
| 753 | = | Ampulla of Vater Adenocarcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581736 |
| 753 | = | Anaplastic Large Cell Lymphoma, ALK-Negative | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581718 |
| 753 | = | BCLC Stage C Hepatocellular Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581737 |
| 753 | = | Bile Duct Adenocarcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581738 |
| 753 | = | Bladder Squamous Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581727 |
| 753 | = | Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581728 |
| 753 | = | Choriocarcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581709 |
| 753 | = | Cystadenocarcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581707 |
| 753 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581742 |
| 753 | = | Diffuse Malignant Mesothelioma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581710 |
| 753 | = | Endometrial Undifferentiated Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581729 |
| 753 | = | Epithelioid Hemangioendothelioma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581719 |
| 753 | = | Germ Cell Tumor of the Vulva | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581744 |
| 753 | = | Hepatocellular Carcinoma by BCLC Stage | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581730 |
| 753 | = | Hereditary Malignant Urinary System Neoplasm | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581711 |
| 753 | = | Hereditary Ovarian Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581712 |
| 753 | = | Hereditary Renal Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581720 |
| 753 | = | Invasive Sarcomatoid Urothelial Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581731 |
| 753 | = | Kidney Carcinoma Molecular Subtypes | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581739 |
| 753 | = | Low-Grade Serous Ovarian Cancer | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581745 |
| 753 | = | Lung Large Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581721 |
| 753 | = | Lymphoepithelial Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581722 |
| 753 | = | Malignant Dermal Neoplasm | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581713 |
| 753 | = | Malignant Sweat Gland Neoplasm | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581723 |
| 753 | = | Metaplastic Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581714 |
| 753 | = | Myeloid Sarcoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581708 |
| 753 | = | Nasopharyngeal Carcinoma by AJCC v8 Stage | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581743 |
| 753 | = | Pleomorphic Rhabdomyosarcoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581732 |
| 753 | = | Primary Cutaneous CD30 Positive T-Cell Lymphoproliferative Disorders | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581748 |
| 753 | = | Renal Medullary Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581747 |
| 753 | = | Sarcomatoid Transitional Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581724 |
| 753 | = | Skin Nodular Basal Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581733 |
| 753 | = | Skin Sarcoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581715 |
| 753 | = | Stromal Sarcoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581716 |
| 753 | = | Superficial Basal Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581734 |
| 753 | = | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581740 |
| 753 | = | Unclassified Renal Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581746 |
| 753 | = | Urinary Tract Squamous Cell Carcinoma | 5 | 54.5 | Medium confidence | clinicaltrials | inputs
ranking row 2581725 |
| 795 | = | Acute Myeloid Leukemia with FLT3/ITD Mutation | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581820 |
| 795 | = | Acute Myeloid Leukemia with FLT3 Mutation | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581816 |
| 795 | = | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581821 |
| 795 | = | Acute Myeloid Leukemia with NPM1 Mutation | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581817 |
| 795 | = | Acute Myeloid Leukemia with Other Genetic Abnormalities | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581808 |
| 795 | = | Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581823 |
| 795 | = | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581822 |
| 795 | = | Adenocarcinoma with Neuroendocrine Differentiation | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581765 |
| 795 | = | Adult Gliosarcoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581791 |
| 795 | = | Adult Malignant Brain Neoplasm | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581809 |
| 795 | = | Aggressive NK-Cell Leukemia | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581766 |
| 795 | = | AIDS-Related Diffuse Large B-cell Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581792 |
| 795 | = | AIDS-Related Non-Hodgkin Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581767 |
| 795 | = | Anal Canal Squamous Cell Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581793 |
| 795 | = | Anal Margin Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581768 |
| 795 | = | Anal Non-Keratinizing Squamous Cell Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581794 |
| 795 | = | Anaplastic Ependymoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581750 |
| 795 | = | Anaplastic Oligoastrocytoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581751 |
| 795 | = | Basaloid Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581752 |
| 795 | = | Basaloid Squamous Cell Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581769 |
| 795 | = | Bladder Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581810 |
| 795 | = | Breast Metaplastic Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581770 |
| 795 | = | Burkitt Leukemia | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581753 |
| 795 | = | Cancer of Unknown Primary, NOS | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581826 |
| 795 | = | Central Nervous System Non-Hodgkin Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581771 |
| 795 | = | Childhood Hodgkin Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581772 |
| 795 | = | Childhood Lymphoblastic Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581773 |
| 795 | = | Childhood Malignant Genitourinary System Neoplasm | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581754 |
| 795 | = | Childhood Malignant Glioma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581795 |
| 795 | = | Childhood Malignant Kidney Neoplasm | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581774 |
| 795 | = | Chronic Myelomonocytic Leukemia-1 | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581796 |
| 795 | = | Embryonal Rhabdomyosarcoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581797 |
| 795 | = | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Involving the Digestive System | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581775 |
| 795 | = | Eye Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581755 |
| 795 | = | Gallbladder Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581811 |
| 795 | = | Gastric Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581776 |
| 795 | = | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581777 |
| 795 | = | Gastric Non-Hodgkin Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581798 |
| 795 | = | Hairy Cell Leukemia Variant | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581778 |
| 795 | = | High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581824 |
| 795 | = | High Grade Endometrioid Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581779 |
| 795 | = | Histiocytic Sarcoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581756 |
| 795 | = | Invasive Bladder Plasmacytoid Urothelial Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581812 |
| 795 | = | Invasive Bladder Sarcomatoid Urothelial Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581813 |
| 795 | = | Invasive Plasmacytoid Urothelial Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581799 |
| 795 | = | Male Breast Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581780 |
| 795 | = | Malignant Extragonadal Germ Cell Tumor | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581757 |
| 795 | = | Malignant Skin Vascular Neoplasm | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581781 |
| 795 | = | Minimally Invasive Lung Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581814 |
| 795 | = | Mixed Germ Cell Tumor | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581749 |
| 795 | = | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581818 |
| 795 | = | MSI-H Colorectal Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581819 |
| 795 | = | Mucinous Cystadenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581758 |
| 795 | = | Neck Squamous Cell Carcinoma of Unknown Primary | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581800 |
| 795 | = | NUT Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581759 |
| 795 | = | Oncocytic Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581782 |
| 795 | = | Parathyroid Cancer | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581825 |
| 795 | = | Pleural Diffuse Malignant Mesothelioma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581783 |
| 795 | = | Primary Central Nervous System Non-Hodgkin Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581801 |
| 795 | = | Primary Peritoneal Transitional Cell Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581784 |
| 795 | = | Primary Peritoneal Undifferentiated Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581785 |
| 795 | = | Rhabdoid Tumor of the Kidney | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581760 |
| 795 | = | Serous Cystadenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581761 |
| 795 | = | Sinonasal Undifferentiated Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581802 |
| 795 | = | Spindle Cell Sarcoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581762 |
| 795 | = | Splenic B-Cell Lymphoma/Leukemia, Unclassifiable | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581763 |
| 795 | = | Subcutaneous Panniculitis-Like T-Cell Lymphoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581803 |
| 795 | = | Supratentorial Glioblastoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581804 |
| 795 | = | Sweat Gland Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581786 |
| 795 | = | Testicular Seminoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581787 |
| 795 | = | Thyroid Gland Anaplastic Carcinoma, Squamous Cell Carcinoma Pattern | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581805 |
| 795 | = | Thyroid Gland Oncocytic Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581764 |
| 795 | = | Tongue Squamous Cell Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581815 |
| 795 | = | Tubular Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581788 |
| 795 | = | Urinary Tract Adenocarcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581806 |
| 795 | = | Urothelial Carcinoma In Situ | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581789 |
| 795 | = | Uterine Corpus Leiomyosarcoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581807 |
| 795 | = | Verrucous Carcinoma | 4 | 52 | Medium confidence | clinicaltrials | inputs
ranking row 2581790 |
| 873 | = | Acute Myelomonocytic Leukemia | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581906 |
| 873 | = | Adult Burkitt Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581907 |
| 873 | = | Adult Soft Tissue Sarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581844 |
| 873 | = | Adult T Acute Lymphoblastic Leukemia | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581879 |
| 873 | = | Aggressive Variant Prostate Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581923 |
| 873 | = | Anal Basaloid Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581880 |
| 873 | = | Anal Canal Cloacogenic Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581908 |
| 873 | = | Anal Margin Squamous Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581881 |
| 873 | = | Anaplastic Pleomorphic Xanthoastrocytoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581830 |
| 873 | = | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581909 |
| 873 | = | B-Cell Prolymphocytic Leukemia | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581831 |
| 873 | = | BCLC Stage B Hepatocellular Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581910 |
| 873 | = | Bladder Neuroendocrine Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581883 |
| 873 | = | Bladder Small Cell Neuroendocrine Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581911 |
| 873 | = | Bladder Urothelial Carcinoma In Situ | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581884 |
| 873 | = | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581882 |
| 873 | = | BRCA Hereditary Breast Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581845 |
| 873 | = | BRCA Hereditary Ovarian Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581846 |
| 873 | = | Breast Tubular Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581885 |
| 873 | = | Castration-Resistant Prostate Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581912 |
| 873 | = | Cervical Cancer by FIGO Stage 2018 | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581913 |
| 873 | = | Childhood Glioblastoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581847 |
| 873 | = | Childhood Malignant Thoracic Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581832 |
| 873 | = | Childhood Osteosarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581848 |
| 873 | = | Childhood WHO Grade 4 Glioma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581914 |
| 873 | = | Choroid Plexus Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581849 |
| 873 | = | Colorectal Squamous Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581850 |
| 873 | = | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581851 |
| 873 | = | Dedifferentiated Chondrosarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581853 |
| 873 | = | De Novo Myelodysplastic Syndrome | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581852 |
| 873 | = | Diffuse Large B-Cell Lymphoma of the Central Nervous System | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581886 |
| 873 | = | dMMR Colorectal Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581924 |
| 873 | = | EBV-Related Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581854 |
| 873 | = | Endometrial Dedifferentiated Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581915 |
| 873 | = | Endometrioid Stromal Sarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581855 |
| 873 | = | Epithelioid Mesothelioma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581856 |
| 873 | = | Esophageal Neuroendocrine Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581857 |
| 873 | = | Extrahepatic Bile Duct Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581925 |
| 873 | = | Extraskeletal Myxoid Chondrosarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581858 |
| 873 | = | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581916 |
| 873 | = | FIGO Grade 2 Endometrioid Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581887 |
| 873 | = | Ganglioneuroblastoma, Nodular | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581888 |
| 873 | = | Giant Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581833 |
| 873 | = | Head and Neck Adenoid Cystic Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581859 |
| 873 | = | Head and Neck Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581834 |
| 873 | = | Head and Neck Mucosal Melanoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581835 |
| 873 | = | Hematologic Neoplasm Associated with Down Syndrome | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581889 |
| 873 | = | Hematologic Neoplasm with Germline Predisposition | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581836 |
| 873 | = | Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Disorder Affecting Multiple Organ Systems | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581860 |
| 873 | = | HER2-Positive Colorectal Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581926 |
| 873 | = | Hereditary Leiomyomatosis and Renal Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581890 |
| 873 | = | Human Papillomavirus-Independent Squamous Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581861 |
| 873 | = | Human Papillomavirus-Related Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581862 |
| 873 | = | Human Papillomavirus-Related Adenosquamous Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581891 |
| 873 | = | Human Papillomavirus-Related Cervical Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581892 |
| 873 | = | Infratentorial Glioblastoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581893 |
| 873 | = | Invasive Bladder Micropapillary Urothelial Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581894 |
| 873 | = | Invasive Micropapillary Urothelial Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581863 |
| 873 | = | Large B-Cell Lymphoma with IRF4 Rearrangement | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581895 |
| 873 | = | Lung Adenosquamous Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581896 |
| 873 | = | Malignant Central Nervous System Germ Cell Tumor | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581864 |
| 873 | = | Malignant Choroid Plexus Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581837 |
| 873 | = | Malignant Leptomeningeal Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581897 |
| 873 | = | Malignant Mastocytosis | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581827 |
| 873 | = | Malignant Ocular Adnexal Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581838 |
| 873 | = | Malignant Sebaceous Gland Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581865 |
| 873 | = | Mast Cell Leukemia | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581866 |
| 873 | = | Medulloblastoma Molecular Subtypes | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581867 |
| 873 | = | Melanoma of Unknown Primary | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581868 |
| 873 | = | Meningeal Melanoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581869 |
| 873 | = | Micropapillary Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581839 |
| 873 | = | Myeloid Leukemia Associated with Down Syndrome | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581840 |
| 873 | = | Nasal Cavity Squamous Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581917 |
| 873 | = | Nodal Peripheral T-Cell Lymphoma with TFH Phenotype | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581928 |
| 873 | = | Oligometastatic Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581898 |
| 873 | = | Oral Cavity Verrucous Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581899 |
| 873 | = | Ovarian Cystadenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581841 |
| 873 | = | Ovarian High Grade Endometrioid Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581900 |
| 873 | = | Ovarian Mucinous Cystadenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581870 |
| 873 | = | Parathyroid Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581927 |
| 873 | = | Platinum-Resistant Lung Small Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581918 |
| 873 | = | Platinum-Sensitive Lung Small Cell Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581919 |
| 873 | = | Prefibrotic Primary Myelofibrosis | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581920 |
| 873 | = | Primary Central Nervous System B-Cell Non-Hodgkin Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581871 |
| 873 | = | Primary Cutaneous Anaplastic Large Cell Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581872 |
| 873 | = | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581901 |
| 873 | = | Primary Intraocular Non-Hodgkin Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581873 |
| 873 | = | Primary Malignant Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581828 |
| 873 | = | Primary Peritoneal Low Grade Serous Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581921 |
| 873 | = | Prostate Adenocarcinoma with Neuroendocrine Differentiation | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581902 |
| 873 | = | Round Cell Sarcoma with EWSR1-non-ETS Fusion | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581874 |
| 873 | = | Sebaceous Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581875 |
| 873 | = | Solid Pseudopapillary Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581829 |
| 873 | = | Solid Pseudopapillary Neoplasm of the Pancreas | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581842 |
| 873 | = | Spindle Cell/Sclerosing Rhabdomyosarcoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581903 |
| 873 | = | Squamous Cell Carcinoma In Situ | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581876 |
| 873 | = | Thyroid Gland Papillary Microcarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581922 |
| 873 | = | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581904 |
| 873 | = | Transplant-Related Malignant Neoplasm | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581843 |
| 873 | = | Urinary Tract Neuroendocrine Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581877 |
| 873 | = | Urinary Tract Small Cell Neuroendocrine Carcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581905 |
| 873 | = | Vulvar Adenocarcinoma | 3 | 47.2 | Medium confidence | clinicaltrials | inputs
ranking row 2581878 |
| 975 | = | Acute Bilineal Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582087 |
| 975 | = | Acute Erythroid Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581957 |
| 975 | = | Acute Megakaryoblastic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581958 |
| 975 | = | Acute Monoblastic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582121 |
| 975 | = | Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581959 |
| 975 | = | Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582134 |
| 975 | = | Acute Myeloid Leukemia with Maturation | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582088 |
| 975 | = | Acute Myeloid Leukemia with Multilineage Dysplasia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582089 |
| 975 | = | Acute Myeloid Leukemia with Myelodysplasia-Related Cytogenetic Abnormalities | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582090 |
| 975 | = | Acute Myeloid Leukemia without Maturation | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582091 |
| 975 | = | Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582132 |
| 975 | = | Adenocarcinofibroma | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581932 |
| 975 | = | Adult Acute Monoblastic and Monocytic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582092 |
| 975 | = | Adult Acute Monoblastic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582122 |
| 975 | = | Adult Acute Monocytic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582123 |
| 975 | = | Adult Acute Myeloid Leukemia with Maturation | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582093 |
| 975 | = | Adult Acute Myeloid Leukemia without Maturation | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582094 |
| 975 | = | Adult Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582124 |
| 975 | = | Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582125 |
| 975 | = | Adult Acute Myelomonocytic Leukemia | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582095 |
| 975 | = | Aggressive Systemic Mastocytosis | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581960 |
| 975 | = | AIDS-Related Anal Carcinoma | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582031 |
| 975 | = | AIDS-Related Carcinoma | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581961 |
| 975 | = | AIDS-Related Kaposi Sarcoma | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581962 |
| 975 | = | AIDS-Related Malignant Anal Neoplasm | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2581963 |
| 975 | = | AIDS-Related Plasmablastic Lymphoma | 2 | 41.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582096 |
Data updated 16 hours agoSource updated unknown1,654 eligible entities · inputs hash f2f5ed2084d93bba6dcb810e